Chemotherapy response score retains prognostic value only in homologous recombination-proficient or PARP inhibitor–naïve high-grade serous carcinoma: a retrospective cohort study

20260 citationsJournal Articlegold Open Access

Authors

M. Teresa Dawid de Vera · Instituto de Investigación Sanitaria La Fe

Iria Rey · Instituto de Investigación Sanitaria La Fe

Beatriz Montero · Hospital Universitari i Politècnic La Fe

Marta Arnáez De La Cruz · Instituto de Investigación Sanitaria La Fe

Manel Montesinos-Albert · Instituto de Investigación Sanitaria La Fe

Pablo Padilla Iserte · Instituto de Investigación Sanitaria La Fe

Abstract

Objective: To evaluate the prognostic value of Chemotherapy Response Score (CRS) in relation to Homologous Recombination (HR) status and PARP inhibitor (PARPi) maintenance in advanced high-grade serous carcinoma (HGSC) Design: retrospective cohort stu

Topics & Keywords

PARP inhibition in cancer therapy Prostate Cancer Diagnosis and Treatment Breast Cancer Treatment Studies

Publication Details

DOI: 10.22541/au.177485619.93731704/v1

Field-Weighted Citation Impact: 0.00

Command Palette

Chemotherapy response score retains prognostic value only in homologous recombination-proficient or PARP inhibitor–naïve high-grade serous carcinoma: a retrospective cohort study

Authors

Abstract

Topics & Keywords

Publication Details